Should I buy Pacira BioSciences, Inc. (PCRX) stock or is it too late?
⭐ The most reliable of them, either direction: Leerink Partners — 64% of its targets hit on this sector (11 calls tested). It aims for $28 (-23 %), call made on September 10, 2026, maturing on September 10, 2027 (34 d ago).
Firm-by-firm track record on Pacira BioSciences, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Jefferies | 71 % | +57.3 % | 14 | $36 -1% |
| Wedbush | 50 % | +53.8 % | 10 | $57 +57% |
| Piper Sandler | 33 % | +16.6 % | 9 | $42 +16% |
| Barclays | 27 % | +14.6 % | 15 | $25 -31% |
| Needham | 37 % | -2.6 % | 27 | $33 -9% |
| HC Wainwright & Co. | 32 % | -6.7 % | 22 | $37 +1% |
| Canaccord Genuity | 29 % | -17.6 % | 7 | $44 +21% |
| RBC Capital | 12 % | -31.5 % | 8 | $37 +1% |
✅ Reasons to believe
- Few solid positives from analysts right now: of 8 ratings, only 1 buys, and the median price target ($37) is barely above the price (+1%, at $36). Caution prevails.
⚠️ Reasons to hesitate
- Even the most reliable firm on PCRX, Jefferies (71% hit rate, 14 scored calls), only targets $36 (call made on October 8, 2026, maturing on October 8, 2027) (-1%) in its most recent call. The stock may already have run past its target.
- The consensus is not unanimous: of 8 ratings, 7 are neutral.
- Limited upside: the median target is only +1% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on PCRX
Median target $37 (+1%) · 8 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Pacira BioSciences, Inc. now?
We won't decide for you. The facts: 13% of analysts rate it a buy, median target $37 (+1%), and Jefferies (most reliable on PCRX, 71%) targets $36. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Pacira BioSciences, Inc.?
The stated upside is small: the median target ($37) sits just +1% from the price ($36) (most reliable on PCRX: Jefferies, 71%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Pacira BioSciences, Inc. still worth investing in?
It depends on the gap between the price ($36) and its estimated value: analysts target $37 on median (+1%), with 13% buys (most reliable on PCRX: Jefferies, 71%). Cross-check with their real reliability on PCRX and the cautions above. Information, not advice.
What's the main risk in buying PCRX?
Even the most reliable firm on PCRX, Jefferies (71% hit rate, 14 scored calls), only targets $36 (call made on October 8, 2026, maturing on October 8, 2027) (-1%) in its most recent call. The stock may already have run past its target.
→ Go deeper: the full Pacira BioSciences, Inc. profile (consensus, analyst reliability, price target, performance).